1142214-62-7 Usage
General Description
AM-1638 is a potent and selective agonist for the cannabinoid CB1 receptor with no affinity for the CB2 receptor. It is a synthetic compound that acts as a full agonist at the CB1 receptor, producing a range of physiological and behavioral effects similar to those caused by the natural cannabinoid tetrahydrocannabinol (THC). AM-1638 has been found to induce hypolocomotion and antinociception in animal models, making it a valuable tool for studying the endocannabinoid system and potential therapeutic applications for CB1 receptor activation. However, its psychoactive effects and potential for abuse make it a subject of careful regulation and control.
Check Digit Verification of cas no
The CAS Registry Mumber 1142214-62-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,4,2,2,1 and 4 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1142214-62:
(9*1)+(8*1)+(7*4)+(6*2)+(5*2)+(4*1)+(3*4)+(2*6)+(1*2)=97
97 % 10 = 7
So 1142214-62-7 is a valid CAS Registry Number.
1142214-62-7Relevant articles and documents
Improving the pharmacokinetics of GPR40/FFA1 full agonists
Du, Xiaohui,Dransfield, Paul J.,Lin, Daniel C.-H.,Wong, Simon,Wang, Yingcai,Wang, Zhongyu,Kohn, Todd,Yu, Ming,Brown, Sean P.,Vimolratana, Marc,Zhu, Liusheng,Li, An-Rong,Su, Yongli,Jiao, Xianyun,Liu, Jiwen,Swaminath, Gayathri,Tran, Thanhvien,Luo, Jian,Zhuang, Run,Zhang, Jane,Guo, Qi,Li, Frank,Connors, Richard,Medina, Julio C.,Houze, Jonathan B.
supporting information, p. 384 - 389 (2014/05/06)
We recently reported the discovery of a potent GPR40 full agonist AM-1638 (1). Herein, we describe our efforts in improving the drug-like properties of the full agonists through the systematic introduction of polar groups in the C-, D-, and A-rings. This led to the discovery of new GPR40 full agonists with significantly improved pharmacokinetic propeties. Compound 8 and 20 also showed potent in vivo efficacy in oral glucose tolerance tests in mice in addition to the improvement in properties.
